SCM
Sio Capital Management Portfolio holdings
AUM
$249M
This Quarter Return
-6.52%
1 Year Return
+117.71%
3 Year Return
+238.99%
5 Year Return
+411.91%
10 Year Return
+912.87%
AUM
$202M
AUM Growth
+$202M
(+7.8%)
Cap. Flow
+$23.9M
Cap. Flow
% of AUM
11.8%
Top 10 Holdings %
Top 10 Hldgs %
75.02%
Holding
61
New
16
Increased
10
Reduced
12
Closed
13
Top Buys
| 1 |
Centene
CNC
|
$27.4M |
| 2 |
GE HealthCare
GEHC
|
$16.2M |
| 3 |
Cigna
CI
|
$8.83M |
| 4 |
Cencora
COR
|
$7.01M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$6.04M |
Top Sells
| 1 |
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
|
$23.4M |
| 2 |
STAAR Surgical
STAA
|
$7.63M |
| 3 |
Icon
ICLR
|
$6.6M |
| 4 |
HSKA
Heska Corp
HSKA
|
$6.53M |
| 5 |
Protagonist Therapeutics
PTGX
|
$4.74M |
Sector Composition
| 1 | Healthcare | 98.68% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Centene
CNC
$14.3B
| $27.4M | 13.53% | +432,834 | New | +$27.4M |
|
|
2
Cigna
CI
$80.3B
| $22.3M | 11.01% | 87,175 +34,564 | +66% | +$8.83M |
|
|
BCYC
3
Bicycle Therapeutics
BCYC
$511M
| $20.6M | 10.17% | 967,347 +283,922 | +42% | +$6.04M |
|
|
4
Cencora
COR
$56.5B
| $20.5M | 10.14% | 128,164 +43,765 | +52% | +$7.01M |
|
5
United Therapeutics
UTHR
$13.8B
| $16.8M | 8.3% | 75,003 +20,044 | +36% | +$4.49M |
|
|
6
GE HealthCare
GEHC
$33.7B
| $16.2M | 7.98% | +196,887 | New | +$16.2M |
|
7
Organon & Co
OGN
$2.45B
| $11.1M | 5.48% | 471,553 -116,283 | -20% | -$2.73M |
|
8
Medtronic
MDT
$119B
| $6.77M | 3.35% | 84,012 -43,988 | -34% | -$3.55M |
|
9
Avantor
AVTR
$9.18B
| $5.99M | 2.96% | 283,136 +33,136 | +13% | +$700K |
|
10
ADC Therapeutics
ADCT
$345M
| $4.21M | 2.08% | +2,160,632 | New | +$4.21M |
|
11
Viking Therapeutics
VKTX
$3.04B
| $4.16M | 2.06% | +250,000 | New | +$4.16M |
|
|
AXNX
12
DELISTED
Axonics, Inc. Common Stock
AXNX
| $3.87M | 1.91% | +70,841 | New | +$3.87M |
|
13
Globus Medical
GMED
$8.27B
| $3.82M | 1.89% | +67,500 | New | +$3.82M |
|
14
Relay Therapeutics
RLAY
$619M
| $3.79M | 1.87% | +230,013 | New | +$3.79M |
|
|
MACK
15
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $3.35M | 1.66% | 272,843 +22,843 | +9% | +$281K |
|
16
Revolution Medicines
RVMD
$7.1B
| $2.73M | 1.35% | +125,957 | New | +$2.73M |
|
|
EUCRU
17
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
| $2.58M | 1.27% | 248,674 | – | – |
|
18
Repare Therapeutics
RPTX
$71.7M
| $2.25M | 1.11% | +228,538 | New | +$2.25M |
|
|
CTIC
19
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $2.21M | 1.09% | 526,239 +196,239 | +59% | +$824K |
|
20
Savara
SVRA
$567M
| $1.85M | 0.91% | 948,457 +82,009 | +9% | +$160K |
|
21
Pharvaris
PHVS
$1.39B
| $1.84M | 0.91% | 228,385 -56,615 | -20% | -$456K |
|
|
HSKA
22
DELISTED
Heska Corp
HSKA
| $1.7M | 0.84% | 17,450 -66,859 | -79% | -$6.53M |
|
|
ELEV
23
DELISTED
Elevation Oncology
ELEV
| $1.67M | 0.82% | 876,611 +516,880 | +144% | +$982K |
|
24
Inogen
INGN
$216M
| $1.52M | 0.75% | 121,535 -165,157 | -58% | -$2.06M |
|
|
NYXH
25
Nyxoah
NYXH
$234M
| $1.41M | 0.7% | 188,875 +172,765 | +1,072% | +$1.29M |
|